BUFFALO, N.Y., Oct. 2, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between CBLI and Bioprocess Capital Ventures today announced a poster presentation at Cell Symposia: Cancer Epigenomics, to be held on October 6-8, 2013 in Meliá, Sitges, Spain.
Katerina Gurova, MD, Ph.D., Assistant Professor of Oncology, Department of Cell Stress Biology, Roswell Park Cancer Institute, will present a poster entitled, "Facilitates chromatin transcription (FACT) complex is an "accelerator" of malignant transformation and potential marker and target of aggressive cancer," on October 7. The abstract presents FACT's role in selective chromatin remodeling of genes involved in cancer transformation. Previous studies observed high levels of FACT expression in aggressive subtypes of tumors with poor prognosis and its critical role in survival of tumors and transformed cells. Over-expression of FACT was found to stimulate oncogene-driven transformation, while suppression of FACT was observed to block it.
FACT is a molecular target for CBL0137, a drug in development by Incuron. The first patient was recently dosed in a multi-center Phase 1 trial evaluating intravenous administration of CBL0137 in patients with metastatic or unresectable advanced solid tumors and lymphomas in the U.S. An ongoing Phase 1 study of oral administration of CBL0137 in patients with advanced solid tumors that are resistant or refractory to standard treatment is being conducted in the Russian Federation.
For more information about the Cell Symposia: Cancer Epigenomics, please refer to: http://www.cell-symposia-cancerepigenomics.com/.
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.
About Incuron, LLC
Incuron, LLC is a Russian Federation based joint venture founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and orphan indications. To learn more about Incuron, LLC, please visit the company's website at http://www.incuron.com/.
This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our regulatory submissions and discussions with regulators, our ability to successfully develop and commercialize our therapeutic products; the conduct and results of our various clinical trials; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.
These factors include, among others, the Company's failure to successfully and timely develop new products; the Company's collaborative relationships and the financial risks related thereto; the Company's ability to comply with its obligations under license agreements; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's inability to obtain regulatory approval in a timely manner or at all; the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern; the Company's need for substantial additional financing to meet its business objectives; the potential for the loss of funding from the Company's R&D grants and contracts and its ability to win additional funding under such grants and contracts. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.
Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439